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INTRODUCTION
Cervical cancer is the third most common malig-
nancy in women, and the seventh in the world,
with approximately 528.000 new cases in 2012.
According to the data from GLOBOCAN 2008, the
incidence of cervical cancer in Indonesia was
13,762 cases, with as many as 7,493 deaths.1 This
high mortality rate is because most patients pre-
sent with locally advanced or terminal stage. Data
in RSCM from 2006-2010, showed that there were
2,297 cases of cervical cancer, with as much as
76.7% locally advanced disease (IIB to IVB).2
According to the National Cancer Institute (NCI),
the five-year survival rate for stage IIB-IIIB cervical
cancer from 1996 to 2000 was 55%, while for stage
IV was 14.6%.3 The five-year survival rate for the
same stage in 2002-2008 was 56.7%, and 16.2%.4
Data from Dharmais Cancer Hospital, Jakarta in
1996, the survival rate of cervical cancer stage I, II,
III, and IV are 56.6%, 56%, 23.7%, and 0% respec-
tively.5 Nuranna et al reported the five-year sur-
vival rate of cervical cancer in RSCM in 2005-2006
for stage I, II, III, and IV to be 73%, 52%, 36%, and
0%, respectively; or the survival-rate of early and
advanced stage to be 67 % and 41%.6
Abstract
Objective: To evaluate the efficacy (treatment response), toxicity,
and overall survival of concomitant chemoradiation (CRT) with
three-weekly cisplatin-ifosfamide compared to CRT with weekly cis-
platin in advanced stage cervical cancers (stage IIB-IIIB).
Method: This is a historical cohort between 32 patients receiving
CRT with three-weekly cisplatin and ifosfamide and 29 patients re-
ceiving weekly cisplatin in Gynecologic Oncology division outpatient
clinic and ward, Dr. Cipto Mangunkusumo Hospital.
Results: There was no significant difference in treatment response,
overall and disease-free survival. There was more gastrointestinal
toxicity in the cisplatin-ifosfamide arm compared to the other arm
(p=0.014), but other toxicity effects were not different.
Conclusion: Platinum based-chemoradiation has the same efficacy
in terms of treatment response for locally advanced cervical cancer.
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Abstrak
Tujuan: Untuk menilai efektivitas (respons terapi), toksisitas, dan ke-sintasan keseluruhan dari kemoradiasi dengan cisplatin-Ifosfamide
tiga mingguan dibandingkan dengan cisplatin mingguan pada kanker
serviks stadium lanjut lokal (stadium IIB-IIIB).
Metode: Studi kohort retrospektif pada 32 pasien yang ditatalaksana
dengan kemoradiasi cisplatin-ifosfamide tiga mingguan dan 29 pasiendengan cisplatin mingguan menjadi subjek penelitian di poliklinik dan
ruangan perawatan divisi Onkologi Ginekologi RSUPN Dr. Cipto Ma-ngunkusumo (RSCM).
Hasil: Tidak terdapat perbedaan bermakna pada efektivitas (responsterapi), kesintasan keseluruhan dan kesintasan bebas penyakit pada
kedua kelompok tersebut. Toksisitas gastrointestinal lebih berat dite-
mukan pada kelompok cisplatin-ifosfamide tiga mingguan dibanding-kan cisplatin mingguan (p=0,014). Sementara, tidak terdapat perbe-
daan bermakna pada toksisitas genitourinaria dan hematologi padakedua kelompok.
Kesimpulan: Kemoradiasi berbasis platinum memberikan efektivitasyang sama terhadap penderita kanker serviks stadium lanjut.
[Maj Obstet Ginekol Indones 2015; 3-4: 212-221]
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This low survival rate for locally advanced
stages of cervical cancer and treatment advances
has triggered the shift of treatment from radiation
to chemoradiation.7-11 In 1999, based on five clini-
cal trials, the National Cancer Institute (NCI) re-
commends the use of cisplatin-based chemoradia-
tion as the standard of patient care with locally ad-
vanced cervical cancer in stage IIB to IVA.12
A meta-analysis by Lukka et al of eight random-
ized clinical trials have evaluated the role of cis-
platin by itself or in combination with other che-
motherapy agents, which was given concurrently
with external radiation, in patients with locally ad-
vanced stage.13 A systematic review from Green et
al showed improvement of overall survival rate
and progression-free survival, 10% and 13% res-
pectively, favoring chemoradiation with cispla-
tin.14
The results of a meta-analysis of 18 randomized
clinical trials by the American Society of Clinical
Oncology, showed that there was a 6% (HR 0.81,
p<0.001) increase in the overall survival rate, and
an 8% increase in the Disease Free Survival (DFS)
for 5 years. These advantages are also supported
by other data demonstrating the improvement in
local control and benefits in distant control are be-
cause of the systemic effects of chemotherapy.15
Available data shows that chemoradiation only
increases the response rate by 20-30%11 and the
5-year survival rate by 6%.10 Efforts to improve the
response to chemotherapy and survival rate in lo-
cally advanced cervical cancer are still continued.
Attempts by using other chemotherapy or com-
bined chemotherapy regimens with concomitant
radiotherapy have been performed.
Geara, in a phase II study comparing chemora-
diation with weekly cisplatin and paclitaxel in pa-
tients with locally advanced cervical cancer, found
no significant clinical benefit.16 Survival rate at two
and five years in the paclitaxel group was 78% and
54%, while in the cisplatin group was 73% and
43%.16
Attempts to perform a combined chemotherapy
regimen have been performed. Ranen Kanti, et al
did not find significant differences in the use of cis-
platin combination chemotherapy with weekly
gemcitabine, with therapeutic response of only
67%.17 Meanwhile, phase III clinical trials by Duen
as-Gonzalez et al done in stage IIB and III cervical
cancer comparing the standard cisplatin chemora-
diation with cisplatin and gemcitabine, as well as
two additional gemzitabin-cisplatin series found a
significant increase in progression-free survival
(PFS) in the third year (74.4% vs. 65.0%,
p=0.029).18
GOG protocol 110 is a prospective, randomized;
phase III study of 454 locally advanced cervical
cancer patients. It found that combination of cis-
platin-ifosfamide is superior to cisplatin alone
(33% compared to 19%). Furthermore, these re-
sults showed superiority in terms of PFS (p=0.003),
although there was no significant difference in the
overall survival rate.19 A phase II prospective study
by Vrdoljak et al observed chemoradiation with
cisplatin-ifosfamide regimen in 62 patients with lo-
cally advanced cervical cancer. Complete clinical
response was achieved in 100% of patients, and
both recurrence-free and overall survival rate was
88.7%.20
Due to GOG 110 study results, efforts in mini-
mizing the effects of full-dose chemotherapy on lo-
cally advanced cervical cancer and improving
therapeutic response and survival rate in locally
advanced cervical cancer, the Gynecologic Oncol-
ogy Division of Obstetrics and Gynecology Depart-
ment, Dr. Cipto Mangunkusumo Hospital has been
using chemoradiation with two chemotherapy
regimens, which is weekly cisplatin and cisplatin-
ifosfamide three weekly as the standard of treat-
ment for locally advanced cervical cancer.
This study will evaluate the existing treatment
regimens in terms of assessing better treatment re-
sponse and survival rate, as well as toxicity profile
as a part of protocol evaluation in the Gynecologic
Oncology division.
METHODS
This is a historical cohort carried out in the Gyne-
cologic Oncology outpatient clinic, radiotherapy
department, and Gynecology Oncology division
ward, Dr. Cipto Mangunkusumo Hospital (RSCM),
from December 2013 until October 2014. The
study subjects are patients who were treated using
chemoradiation using cisplatin-ifosfamide and
weekly cisplatin in RSCM from August 26th 2010
until June 28th 2014 who met the inclusion criteria.
The total sample size in this study was 61 patients.
The inclusion criteria are stage IIB-IIIB cervical
cancer patients who received chemoradiation with
3-weekly cisplatin-ifosfamide or weekly cisplatin,
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with performance status based on the Eastern Co-
operative Oncology Group (ECOG) criteria with
score ≤2; having peripheral blood result of Hb
≥10g%, leukocyte ≥5000/mm3, thrombocyte
≥150,000/mm3; SGOT <27U/l, SGPT <36 U/l); and
renal status of ureum <50 mg/dl, creatinin 0.60-
1.20 mg/dl, CCT >68 ml/minute; had been given at
least 3 series of chemotherapy; had the tumor size
examined with transrectal USG; and underwent
post-therapy follow up in the gynecologic oncology
outpatient clinic of RSCM for at least 3 months
post-therapy.
The exclusion criteria are cervical cancer pa-
tients with histopathologic findings other than
squamous cell carcinoma, adenocarcinoma, and
adenosquamous carcinoma; received any previous
therapy including surgery, radiation, or chemora-
diation; suffering other severe comorbidities (un-
controlled cardiovascular disease, uncontrolled
diabetes mellitus, severe psychological impair-
ment, active peptic ulcer) or immunodeficiency/
HIV; having primary cancer in other organs (syn-
chronous tumor); and incomplete radiation the-
rapy.
The steps of this study are, after receiving ethical
clearance; the medical records of the locally ad-
vanced cervical cancer patients (IIB-IIIB) in the
gynecologic oncology outpatient clinic who under-
went one of the two chemoradiation therapies
were collected. The medical data was taken from
patients who were diagnosed from August 2010
until November 2013. Selection of medical records
corresponded to the inclusion and exclusion crite-
ria. The demographic data, clinicopathologic data
in the medical record, and data added upon pa-
tients’ admission were recorded. Radiation is di-
vided into external radiation (2.0 Gray, 5 dose/
week, 25 times) and internal radiation/brachy-
therapy (2 x 8.50 Gray (850 rad) or 3 x 7 Gray at
point A). Meanwhile, chemotherapy was divided
into weekly cisplatin regimen (40 mg/m2 dose in
6-8 hour prior to radiation, 1 dose/week, minimal
3 times), and cisplatin-ifosfamide regimen (cis-
platin 50 mg/m2 and ifosfamide 2 gr/m2 given with
uromitexan, for 3 weeks, 4 series). Chemoradiation
response was evaluated by degree of tumor regres-
sion, defined by comparison between tumor size
prior to and 3-months after therapy. The patients
were then evaluated every month during therapy
to observe the toxicity, until 3-months after the
therapy was completed. The follow-up data in-
cluded recurrence, data from the last visit, patient’s
latest condition, which were all documented from
the medical records. Patient’s latest condition was
inquired through telephone to determine whether
the patients last condition.
The statistical analysis included descriptive ana-
lysis, bivariate analysis, and survival rate analysis
with Kaplan-Meier method. All the data analysis
was performed using STATA ver 10 (Stata Corpo-
ration LP., Texas, USA).
Independent variable in this study is the type of
cervical cancer therapy, whereas the dependent
variables are the treatment response (complete
response, partial response, stable tumor, and pro-
gressive tumor), survival rate (overall survival and
disease free-survival), and toxicity (gastrointesti-
nal, genitourinary, and hematological toxicities).
However, the confounding variables included age,
education, parity, cervical cancer staging based on
FIGO (IIB, IIIA, IIIB), tumor size, performance sta-
tus, histopathologic findings, tumor differentiation,
cervical cancer therapy, and radiation overall treat-
ment time (OTT).
RESULTS
There were 61 cases that fulfilled the selection cri-
teria, with 32 cases receiving cisplatin-ifosfamide
chemoradiation and 29 cases receiving weekly-cis-
platin chemoradiation.
Assesment of treatment response between the
two groups was performed at 3 months after com-
pletion of radiation therapy, and done through gy-
necological and ultrasound examination.
From the figure above, we obtained a hazard ra-
tio (HR) of 1.4, but it was not found to be statisti-
cally significant (p=0.71). From the DFS rate there
is intersection of the curve that did not fulfill the
HR assumption. It showed no statistical signifi-
cance (p=0.78).
Evaluation of toxicity between radiation group
and chemoradiation group was performed based
on RTOG and ECOG criteria. There were gastroin-
testinal toxocity, genitourinary toxicity, and hema-
tologic toxicity, which were the most common toxi-
cities encountered and mentioned in published ref-
erences.
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Table 1. Distribution of the Clinicopathologic Characteristics Based on Type of Chemoradiation
Clinicopathologic characteristics
Cisplatin­Ifosfamide
(n=32)
Weekly Cisplatin
(n=29)
Total p­value
n % n % n %
Performance status 0 19 59.4 21 72.4 40 65.6 0.487
1 13 40.6 4 13.8 17 27.9 
2 0 0,0 4 13.8 4 6.5
Stage IIB 9 28.1 8 27.6 17 27.9 0.863
IIIA 1 3.1 1 3.4 2 3.3
IIIB 22 68.8 20 69.0 42 68.8
Tumor size <4 cm 10 31.25 12 41.4 22 36.1 0.370
>4 cm 22 68.75 17 58.6 39 63.9
Histopathology type Squamous cell carcinoma 23 71.9 18 62.1 41 67.2 0.700
Adenocarcinoma 7 21.9 9 31.0 16 26.2 
Adenosquamous
Carcinoma
2 6.2 2 6.9 4 6.6
Degree of Differentiation Well 7 21.9 8 27.6 15 24.6 0.831
Moderate 18 56.2 16 55.2 34 55.7
Poor 7 21.9 5 17.2 12 19.7
OTT* <62 days 13 40.6 17 58.6 30 49.2 0.160
>62 days 19 59.4 12 41.4 31 50.8
Total 32 100 29 100 61 100
aPearson chi-square test*OTT/Overall Treatment Time: Total period of radiation therapy from the first external radiation to the last internal radiation.
B
 
A 
Figure 1. Overall Survival (A) and Disease-Free Survival (B) Rate based on Type of Chemoradiation.
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DISCUSSION
This study is a historical cohort study on locally
advanced cervical cancer (Stage IIB, IIIA, and IIIB)
in the Division of Gynecologic Oncology, Depart-
ment of Obstetrics and Gynecology, RSCM. In the
period of December 2013 to October 2014, we ob-
tained 61 samples that meet the inclusion criteria
and completed follow-up for up to three months
after completing treatment, which consisted of 32
cases who received chemoradiation therapy with
three-weekly cisplatin-ifosfamide, and 29 cases
who received chemoradiation therapy with weekly
cisplatin. These patients received chemoradiation
treatment between August 26, 2010 to June 28,
2014.
This study has limitations because the sample
size is relatively small, and employed historical co-
hort as research design so that there was no ran-
domization in sample collection. The advantages of
this research is that the treatment response was
assessed for three months after finishing radiation
treatment and monitoring was continued after-
ward with minimal period of monitoring of up to
three years.
Table 2. Comparison of Treatment Response According to Type of Chemotherapy
Treatment Response Cisplatin­Ifosfamide
n (%)
Weekly Cisplatin
n(%)
Total
n(%)
Complete response 30 (93.8) 26 (89.7) 56 (91.8)
Partial response 2 (6.2) 1 (3.4) 3 (4.9)
Stable tumor 0 (0) 0 (0) 0 (0)
Progressive tumor 0 (0) 2 (6.9) 2 (3.3)
Total 32 (100) 29 (100) 61 (100)
Pearson chi-square test; p = 0.290
Table 3. Distribution of Toxicity Based on Type of Chemoradiation
Toxicity
Therapy
Total n (%) p­valueCisplatin­Ifosfamide Weekly Cisplatin
n % n %
Gastrointestinal
Degree 0 - - - - -
Degree 1 10 31.3 11 37.9 21 (35)
Degree 2 22 68.7 18 62.1 40 (65) 0.014
Degree 3 - - - -
Total 32 100 29 100 61 (100)
Genitourinary
Degree 0 - - - -
Degree 1 29 90.6 26 89.7 55 (90.2)
Degree 2 3 9.4 3 10.3 6 (9.8) 0.337
Degree 3 - - - -
Total 32 100 29 100 61 (100)
Hematologic
Degree 0 - - - - -
Degree 1 12 37.5 13 44.8 25 (41)
Degree 2 14 43.8 14 48.3 28 (45.9) 0.331
Degree 3 6 18.7 2 6.9 8 (13.1)
Total 32 100 29 100 61 (100)
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Of the 61 subjects in the study, we obtained an
age range of 35-66 years old, with a mean of 49
years old. Similar results were obtained in phase II
multicenter clinical study conducted by Kato et al
in 2009 in China, Philippines, and Vietnam; where
the mean age was 48.5 years old.18
Cornain et al reported that the incidence of cer-
vical cancer at age over 50 years old is two times
higher (13.9/100,000) than at under 50 years
(6.7/100,000), and the highest distribution is in the
45-49 years old group.21 Research conducted by
Aziz MF in RSCM in 2001 stated a risk of develop-
ing cervical cancer over the age of 50 years to be
higher than that of those under the age of 50 years
with an OR of 2.53 (95% CI 1.27 to 5.05).22
Nuranna et al in 2011 have reported the distribu-
tion of characteristics of cervical cancer in the Di-
vision of Gynecologic Oncology RSCM, with the
highest frequency being in the 35-64 year age
group which constituttes 87.3% of cases.2 Guna-
wan et al in 2012, found that more than 50% of
patients with cervical cancer aged 46-68 years.23
Moreover, Nuranna et al in 2014 in Dr. Cipto Ma-
ngunkusumo found 66.2% of cervical cancer pa-
tients were aged 30-49 years and 33.1% were aged
>50 years.6
Range of parity of the sample in this study is 0
to 8, with a mean of 3.29 ± 1.7 children. The highest
frequency is in the parity >2 group (60.1%), while
in the parity 1-2 was 36.1%. MF Aziz in his re-
search reported cervical cancer cases with parity
≥6 was up to 78 cases (75%), compared to the pa-
rity 0-1, which was 49 cases (25%).22 In this study,
the largest proportion of cervical cancer cases be-
longed to the 40-60 years old age group, with equal
education level of elementary, junior high, or high
school, which was 34.4%, 31.2%, and 34.4%.
The highest number of cervical cancer cases is
in stage IIIB with 42 cases (68.9%), while stage IIB
had 17 cases (27.9%) and there were only 2 cases
of stage IIIA cancer (3.28%). Similar findings were
observed on multicenter clinical investigations
conducted by Kato et al.18 Negi R et al supported
this study with similar proportion of cases; 34
cases of stage IIB (38%), 54 cases of stage IIIB
(60.7%), and only 1 case of stage IIIA (1.1%).24
Gunawan et al in Dr. Cipto Mangunkusumo in 2012
obtained 16 cases of stage IIIB and 15 cases of
stage IIB.23
Tumor size <4 cm was found in 22 cases
(36.1%), 10 cases in the group of cisplatin-ifosfa-
mide and 12 patients in weekly cisplatin, whereas
tumor size >4 cm was found in 22 cases (68.8%)
in the cisplatin-ifosfamide group, and 17 cases
(58.6%) in the weekly cisplatin group. Rose PG et
al also found a similar distribution of tumor diame-
ter, tumors ≤40 mm with 76 cases (14.7%) and
>40 mm with 440 cases (85.3%) in locally ad-
vanced cervical cancer.10 Kong et al found 215
cases with tumor size >4 cm and 40 cases with size
<4 cm.25 Gunawan et al also observed that the
more common tumor diameter is >4 cm for 28
cases, compared to the size of <4 cm with only 4
cases.23 Another study conducted by Nuranna et al
in 2014 found that 74.4% of cases had tumor size
>4 cm, and only 25.3% had tumor size <4 cm.
These study findings support a similar charac-
teristic in terms of tumor size.6
Median ECOG performance status of the patient
is 0 and 1. There were only four subjects with
ECOG 2 (13.8%) in the group of weekly cisplatin.
Similar distribution was found in the study con-
ducted by Kato et al in the Philippines and Vietnam,
where they found a score of 0 in 12 cases and 10
cases.18 Restriction of ECOG score <2 was done in
order to avoid bias in the results of treatment res-
ponse due to patient’s physical condition.
The most commonly encountered histopatho-
logic type is squamous cell carcinoma with 41
cases (67.2%), followed by adenocarcinoma con-
sisting of 16 cases (26.2%), and 4 cases (6.6%) of
adenosquamous type. This finding is consistent
with another study by Nuranna et al in 2011 in
RSCM found that the most common histopathologic
type of cervical cancer is squamous cell carcinoma
with 1322 cases (70.2%) and 285 adenocarcinoma
cases (15%).2 Sakata et al in Japan (2008) also re-
ported 231 cases of squamous cell carcinoma
(94.2%) and 11 cases of adenocarcinoma (4.9%),
while for adenosquamous was not encountered
among the 226 cases.26 Rose et al encountered the
same results, with 472 cases of squamous cell car-
cinoma (89.7%), while there were only 18 cases of
adenocarcinoma (3.4%).10 Kanti et al obtained the
distribution of squamous cell carcinoma to be 56
cases (86.5%), 4 cases of adenosquamous (5.9%),
and 5 cases of adenocarcinoma (7.6%) of a total of
67 cases.17 Kong et al showed similar results,
namely squamous cell carcinoma for 238 cases, fol-
lowed by adenocarcinoma and adenosquamous
carcinoma at 9 cases.25 Another study in 2014 by
Nuranna et al, found 71.6% squamous cell carci-
noma, followed by 11.9% adenocarcinoma and
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13.6% adenosquamous, which was concordant
with the other studies.6
The degree of differentiation holds a role in pre-
dicting the prognosis of cervical cancer. In general,
a poorer differentiation may indicate a worse prog-
nosis.27 In this study, 34 cases (55.74%) were mo-
derately differentiated, 15 cases (24.59%) were
well differentiated, and 12 cases (19.67%) were
poorly differentiated. Similar to our results, the
study by Gunawan et al found that 23 cases
(71.88%) were moderately differentiated, then 7
cases (21.87%) with well differentiation, and 2
cases (6.25%) with poor differentiation.23 Nuranna
et al in 2014 showed moderate differentiation
made up 55.2%, 20.6% were well-differentiated,
and 16.6% with poor-differentiation.6
Evaluation of the confounding demographic and
clinicopathologic variables such as age, perform-
ance status, stage, tumor size, histopathologic type,
degree of differentiation, and OTT radiation in both
treatment groups showed no statistical signifi-
cance. This result showed that there was an equal
distribution of confounding variables in both
groups of chemoradiation types. Thus, the effect of
confounding variable can be eliminated.
In our study, treatment response was assessed
three months after treatment in either groups with
adjuvant concurrent chemoradiation of 40 mg/
m2/week cisplatin or chemoradiation with cis-
platin-ifosfamide three-weekly. According to the
operational definition, treatment response can be
divided into complete response, partial response,
stable tumors, and progressive tumors. In the
group of cisplatin-ifosfamide, as many as 30 pa-
tients had a complete response (93.8%), and 2 pa-
tients had partial response (6.2%). This result is
worse compared to the study by Vrdoljak et al, who
achieved 100% complete response. Meanwhile in
the group receiving cisplatin alone, as many as 26
patients achieved complete response (89.7%), 1
patient had partial response (3.4%), and 2 patients
had progressive tumor (6.9%). There was a total
of 5 patients (8.2%) who did not achieve complete
response consisting of 3 cases (4.9%) who had par-
tial response and 2 cases (3.3%) who had progres-
sive tumor.
Two cases of partial response belonged to the
cisplatin-ifosfamide group, and 1 case in the
weekly cisplatin group. All cases with progressive
tumors were from the weekly cisplatin group. Al-
though no significant difference were found in the
results of this response assessment, result of pro-
gressive tumor needs special attention because it
represents an unresponsive condition.
Radiation protocols used in this study was 50
Gray external radiation and 2 x 8.50 Gray (850 rad)
or 3 x 7 Gray for internal radiation. The duration
of radiation was similar between both study
groups. Similarly, Negi et al used a total dose of 81
Gray to point A with OTT anticipated to be 7 to 10
weeks.24 Vrdoljak et al employed external radiation
dose of 45 Gray plus 2x30 Gray internal radia-
tion.20 Kong et al employed 45 Gray external radia-
tion in 25 fractions over 4-5 weeks with internal
radiation of 30 Gray in 5 fractions at 1-week inter-
vals.25 This varying results may due to retrospec-
tive study. If any future prospective study is to be
conducted, the type of radiation and radiation
scheme employed should be determined in detail
so that the radiation dose will be consistent.20
In this study, the median OTT was 63 days. In
the group of cisplatin-ifosfamide, average OTT is
69 days, while the average for weekly cisplatin is
59 days. OTT for radiation is divided into two cate-
gories, OTT <62 days and >62 days. There were no
significant differences in the distribution of radia-
tion OTT in both study groups. Although radiation
OTT variable in this study is a confounding vari-
able, assessment of treatment response in both
groups showed no significant difference (p=0.61).
We should also consider that in the group with
OTT <62 days, there were two cases that under-
went progressive tumors, while in the group of
more than 62 days there were three cases with
partial response.
In a study conducted by GOG 85, GOG 120 and
RTOG 90-01 the median OTT were 64, 63 and 58
days, respectively.10,11,28 Unlike the GOG 85 and
RTOG 90-01 study, in this trial the median OTT was
similar with GOG 120, which was 63 days. Rose et
al obtained results of median OTT being 63 days
in the chemoradiation with cisplatin group, 65 days
in the chemoradiation using cisplatin + fluoro-
uracil + hydroxyurea group, and 62 days in the
chemoradiation with hydroxyurea group.10
From the data obtained, survival analysis was
performed to evaluate the OS and DFS. DFS was
assessed from 8 cases that experience recurrence
among the 56 cases. Recurrence was diagnosed on
physical examination, histopathologic, and imaging
data found in the medical record. There were 8
cases of recurrence, in both treatment groups.
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There was no local recurrence in both groups.
There were 4 cases of regional recurrence in both
treatment groups, also 4 groups of recurrence with
distant metastases to lungs and liver as target or-
gans.
Two-years survival rate of cisplatin-ifosfamide
was 89.4%, while for cisplatin alone was 86.5%.
Vrdoljak et al reported DFS and OS of 88.7% at a
median follow-up of 4 years.20
The survival curve showed that there was a haz-
ard ratio of 1.4 in the sense that at any time there
was a probability of death of 1.4 times in the cis-
platin-ifosfamide compared to the cisplatin alone
group. However, this difference was not proven to
be statistically significant (p=0.71).
In terms of disease-free survival rate, in the cis-
platin-ifosfamide group was 87.1% in the first year,
while it was 82.7% in the cisplatin group. However,
in the second year, cisplatin-ifosfamide DFS drop-
ped to 68.8%, while cisplatin alone was maintained
at 82.7%. (p=0.78). The presence of disease-free
survival rate curve intersection occurred because
of the design of retrospective study, causing no fur-
ther monitoring protocol, instead relying solely on
data contained in the medical record. Apart from
the problem of data validity, this picture can be
seen from the medical records of the two-year re-
currence and after treatment monitoring.
Kong et al also found no significant difference in
progression-free survival (PFS) rate and on the
overall survival rate in the chemoradiation group
compared with weekly chemoradiation to be
74.6% vs 64.3% and 78% vs. 73% (p=0.7105 and
p=0.237).25 While Roy found the 16-month DFS
rate of 83% in the cisplatin chemoradiation with
gemcitabine compared to 73% in weekly cis-
platin.29 Based on this DFS rate, other types of regi-
men were found to not be better than cisplatin-
ifosfamide.
In this study, the incidence of degrees 0 acute
toxicity was not found in terms of gastrointestinal,
genitourinary, and hematology toxicities. Proven
gastrointestinal toxicity was significantly different
(p=0.014). Distribution shows that the most com-
mon degree of gastrointestinal toxicity was grade
2, complaining of nausea and vomiting which re-
quired antiemetic or abdominal pain which re-
quired analgesics, diarrhea that required treat-
ment, rectal and abdominal pain requiring analge-
sics. There were 22 cases (68.7%) in the cisplatin-
ifosfamide therapy group and 18 cases (62.1%) in
the cisplatin group who experienced toxicity de-
gree 2. A total of 21 cases (35%) were spread
evenly in both treatment groups who experienced
toxicity grade 1 in the form of nausea and abdomi-
nal discomfort which did not require any treat-
ment, or increased frequency of bowel, or anal sore
that did not require medication.
Kong et al also found that gastrointestinal toxici-
ty is more common in monthly compared to
weekly chemoradiation, 6 cases compared to 22
cases.25 This toxicity included diarrhea (4 cases on
monthly chemoradiation and 2 cases on weekly
chemoradiation), nausea (17 cases in the monthly
chemoradiation and 2 cases in weekly chemoradia-
tion), and vomiting (11 cases on monthly chemora-
diation and 7 cases on weekly chemoradiation).
In genitourinary toxicity, the highest degree of
toxicity was grade 2 in the form of urinary fre-
quency/nocturia less than every 1 hour, dysuria, ur-
gency and bladder spasms that require treatment.
There were three cases in each treatment group
with grade 2 toxicity (9.4% and 10.3%). While 52
cases (90.2%) experienced grade 1 toxicity in the
form of urination two times more often than usual,
dysuria, or who did not require emergency treat-
ment (90.6% in cisplatin-ifosfamide and 90.2% in
cisplatin alone). There was no significant difference
in terms of genitourinary toxicity (p=0.337).
Hematologic toxicity grade 3 in the form of ane-
mia with hemoglobin level reaching 6.5-8 g/dl, or
leukopenia (2000-3500 leukocytes/μl), or throm-
bocytopenia (platelet 50,000-100,000/μl) occurred
in 18.7% of cases in the cisplatin-ifosfamide group
and 6.9% of cases in the cisplatin alone group.
While toxicity level 1 and 2 were distributed evenly
in the two treatment groups. There were no signifi-
cant differences between the two treatment groups
in terms of hematologic toxicity (p=0.331).
Kong et al showed that the toxicity of monthly
chemoradiation was greater than weekly chemora-
diation, with 22 cases compared to 12 cases. A total
of 7 cases on a monthly chemoradiation were ane-
mic, more than that found in weekly chemoradia-
tion, which were only 3 cases.25 Likewise, leuko-
penia on monthly chemoradiation amounted to 11
cases, while weekly chemoradiation only had 7
cases. Thrombocytopenia in monthly chemoradia-
tion consists of 4 cases, more than weekly chemora-
diation with only 2 cases.
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Major acute toxicity can be seen in hematologic
and gastrointestinal toxicity. There were no treat-
ment-related deaths. None of the patients stopped
the chemotherapy by request or due to its toxicity.
Overall, these three toxicity effects were treatable
with appropriate therapy according to patient’s
complaints, thus preventing incomplete therapy.
CONCLUSION
Chemoradiation with three-weekly cisplatin-ifosfa-
mide and weekly cisplatin have the same efficacy
in patients with locally advanced cervical cancer,
but weekly cisplatin chemoradiation is more toler-
able. Our historical cohort design may bring about
selection bias, that may affect the results of the
study even though it had been minimized by per-
forming confounding variables equality test. In ad-
dition, this study used a long period of monitoring
time and closed data that may affect the validity of
the results.
Nevertheless, the treatment of locally advanced
stage cervical cancer in consideration of control of
local recurrence, regional and distant recurrence re-
mains an issue, thus allowing another potential
therapy combination. It is suggested to conduct a
multicenter randomized trial of prospective cohort
to investigate new chemotherapy regimens assess-
ing effects of particular radiosensitizer and the ef-
fects of chemotherapy in cervical cancer in order to
improve the survival and quality of life of patients
with locally advanced cervical cancer.
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